https://www.barrons.com/articles/astrazeneca-stock-cancer-drug-results-disappoint-933bc35e
0
0
7/3/23 at 3:02pm
Organization
Barron's
Author
Angela Palumbo
36 words
0
Comments
American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug.
You are the first to view
Create an account
or login to join the discussion